# An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

> **NCT03510884** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 153 (actual)

## Conditions studied

- Hypercholesterolaemia

## Interventions

- **DRUG:** Alirocumab SAR236553 (REGN727)
- **DRUG:** Rosuvastatin
- **DRUG:** Atorvastatin
- **DRUG:** Simvastatin
- **DRUG:** Pravastatin
- **DRUG:** Lovastatin
- **DRUG:** Fluvastatin
- **DRUG:** Ezetimibe
- **DRUG:** Cholestyramine
- **DRUG:** Nicotinic acid
- **DRUG:** Fenofibrate
- **DRUG:** Omega-3 fatty acids
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03510884
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-31
- **Primary completion:** 2021-01-14
- **Final completion:** 2022-08-05
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03510884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03510884, "An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03510884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*